USFDA16 May 2026, 03:00 pm
Emcure Pharma: US FDA Inspects Sanand Facility, Issues Form 483
AI Summary
The United States Food and Drug Administration (US FDA) conducted a cGMP inspection at Emcure Pharmaceuticals' formulations facility in Sanand, Ahmedabad, Gujarat, from May 6, 2026, to May 15, 2026. At the conclusion of the inspection, the company received a Form 483 with 7 observations, which are procedural in nature. Emcure plans to address these observations comprehensively and respond to the US FDA within the stipulated timeframe.
Key Highlights
- US FDA inspected Emcure's Sanand formulations facility.
- The inspection took place from May 6 to May 15, 2026.
- A Form 483 was issued with 7 procedural observations.
- Emcure will respond to the US FDA within the required timeframe.